Table S3. Characteristics of liver cirrhosis at baseline

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All (n=200)** | **LLV (n=60)** | **MVR (n=140)** | ***P*** |
| Age, years | 49 (44, 55) | 50 (44, 53) | 49 (43, 55) | 0.553 |
| Male, % | 153 (76.5%) | 50 (83.3%) | 103 (73.6%) | 0.136 |
| HBeAg positive, % | 81 (40.9%) | 28 (46.7%) | 53 (38.4%) | 0.277 |
| HBV DNA, log10 IU/L | 5.12 (3.41, 6.14) | 5.82 (3.50, 6.29) | 4.63 (3.15, 5.97) | 0.050 |
| Platelet, 109/L | 97 (65, 135) | 95 (69, 134) | 108 (69, 143) | 0.261 |
| ALT, U/L | 56 (35, 93) | 63 (35, 92) | 55 (37, 92) | 0.952 |
| AST, U/L | 50 (36, 78) | 50 (38, 72) | 49 (35, 81) | 0.887 |
| Bilirubin, mmol/L | 17.7 (13.3, 26.1) | 17.4 (14.0, 25.2) | 16.3 (12.5, 22.8) | 0.345 |
| Albumin, mg/L | 42.8 (38.1, 45.5) | 43.8 (41.8, 46.6) | 43.6 (40.4, 45.6) | 0.439 |
| Treatment naïve, % | 171 (85.5%) | 48 (80.0%) | 123 (87.9%) | 0.148 |
| Treatment |  |  |  | 0.006 |
| First-line drugs, % | 158 (79.0%) | 40 (66.7%) | 118 (84.3%) |  |
| Non-first-line drugs, % | 40 (20.0%) | 20 (33.3%) | 20 (14.3%) |  |
| Non-first-line drugs combined first-line drugs, % | 2 (1.0%) | 0 (0%) | 2 (1.4%) |  |

LLV, low-level viremia; MVR, maintained virological response; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PLT, platelets.